Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type8 |( J. Y& a+ F: k! ?
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 ) X8 q. G( N+ Z9 u7 p
+ Author Affiliations
2 z; A3 h( p( |
. _6 K. r$ n. _! Y4 [: U1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 5 t6 Q+ ~: e, n% |0 _* F
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
/ X( w- _" n- E4 m4 _# \3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
% w1 G6 m! o3 Q. ]1 M4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
H+ o5 r# H6 G# e, Q- o' S/ i5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
{6 |! ]$ \- y- w" e6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan / ~7 V2 q3 z" m$ ?, b3 |8 l
7Kinki University School of Medicine, Osaka 589-8511, Japan & U1 u$ c% I( t Y& f2 n
8Izumi Municipal Hospital, Osaka 594-0071, Japan ' h7 n' ?4 p) ~$ i
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
# d; \" P' L% j. U oCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 4 u6 \ T7 Q' r# G
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. ! {! z! U3 {8 ?3 @' |. t( b8 c
8 x& r. i7 ]) f( K
|